Working Party Abstract: Introduction: In survival analysis, when the observation of a survival time of interest is incomplete, we deal with censoring. Even if diff erent types of censoring arise in practice, the most studied in the literature is the right censoring, i.e. when some patients are known to be alive event-free at the end of follow-up or are lost to follow-up. However there also exist left and interval censoring. The latter one occurs when for some patients the exact date of occurrence of the event is unknown, but lies in an identifi ed interval. Our aim was to extend the current knowledge on interval censored estimation and promote its practical application in clinical trials. Materials and Methods: We considered the problem of estimating the survival probability at a fi xed time point, which is a common endpoint in phase II trials. We compared the performance of the Kaplan-Meier and Turnbull estimators on various sets of simulated data. Various scenarios were simulated according to diff erent amount of missing assessments (10%, 20%, 30% and 40%), length of intervals between observations (30, 60 and 90 days) and random error for timing of observations (5, 10 and 15 days). The bias and the coverage probability (performance of the confi dence limits estimation) were compared between the two methods, assessing separately the importance of each element of the simulation in aff ecting bias and coverage. Results: Estimation with the Kaplan-Meier resulted always overestimated compared to the Turnbull estimator. The bias of KaplanMeier remarkably increased with the percentage of missing assessments and with the length of observation intervals; the diff erence was less evident according to diff erent timing errors. Confi dence intervals of Turnbull were generally larger than Kaplan-Meier ones. Both methods were sensitive to whether the targeted timepoint is a multiple of the periodicity of observation. Discussion: The bias of the Kaplan-Meier method in assessing the true value may importantly aff ect the design of a Phase II trials in some cases. Most sensitive situation occurred when only a few assessments took place before the time point of interest. Disclosure of Interest: None Declared. Working Party Abstract: Hematopoeitic stem cells transplantation (HCST) is a highly technical procedure, requiring trained staff and dedicated units. In terms of clinical research, low incidences in HSCT-treated malignancies often lead to multicentre designs in order to achieve suffi cient sample sizes for HSCT studies. So-called centre eff ect has been recurrently investigated to assess centre heterogeneity [1][2][3]. However the underlying clinical question(s) is(are) not always transparent. Centre eff ect could relate to either a baseline heterogeneity of the endpoint distribution among centres, or an heterogeneity of a covariate eff ect among centres (for instance the treatment eff ect in clinical trials, with a treatment-by-center interaction), or both. To these diff erent questions correspond diff erent inference statistical methods that need to be used appropriately. Of course, they apply to continuous, categorical or survival endpoints.
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With an illustrative example in hematology, we propose to present the main concepts of centre heterogeneity and how it can be accounted for in planning, analyzing and reporting multicentre clinical studies. Working Party Abstract: The use of multi-state models to model complex disease histories has been advocated for over a decade; however, its use in clinical applications has been limited so far. Some reasons for this are lack of familiarity with the methods, insuffi cient data to describe post-SCT disease histories in enough detail, and oversimplifi ed models not taking into account relevant clinical issues. We will show an example where we tried to bridge the gap between statistical methodology and clinical questions. Our main outcome of interest is the probability of treatment succes over time. Since all patients enter and leave this state at diff erent time points, methods of classical survival analysis cannot be applied to estimate this quantity. This outcome is very relevant to assess the quality of treatment success of transplanted patients, impacting their well-being. The model will be used to analyse a dataset describing post-transplant events of a cohort of CLL (chronic lymphocytic leukemia) patients collected by the EBMT in the CLL Data Quality Initiative of the CMWP. In contrast to most similar datasets, it contains surrogate information about the end of cGvHD in addition to data about the start of cGvHD. Patients and methods: Data of 424 patients were available for the fi rst analysis (median age 55, 39% HLA-identical donor; 11% in CR at SCT, 56% in PR, 33% stable/progressive disease). We defi ne treatment success as the absence of disease, of cGvHD requiring immuno-suppressive treatment (IS) and of prophylactic IS for GvHD. 157 of the patients in the dataset experienced a period of treatment success.
Dynamic prediction methods were applied to update the estimate of the probability of treatment success based on more information about the patient's post-SCT disease course become available over time, eg, if the patient experienced extensive cGvHD. Moreover, by adding weights to the diff erent states, quality-adjusted summaries of the outcomes can be estimated. All analyses will incorporate relevant predictors at baseline. They will be performed by means of the 'survival' and 'mstate' packages in R.
Results: The probability of treatment success strongly depends on risk factors at baseline. Our model shows that especially good risk patients have a considerable probability of achieving treatment success and maintaining it. An episode of extensive cGvHD considerably decreases this probability. Discussion: The current study shows the potential of multi-state models in the analysis of clinically meaningful outcomes if the necessary conditions-incorporation of clinical aspects in the model and the use of appropriate data-are fulfi lled. Introduction: Accurate patient data reporting is essential for the validity of the scientifi c conclusions based on the international databases (DB) of CIBMTR and EBMT. A study request from EMBT listing patients with CML, raised suspicion that the list was incomplete and that data had not been correctly reported. To identify if data were missing and if so whether the problem was, a) internal (local DB, data entering etc.), b) external (EBMT/CIBMTR DB), c) random, or d) systematic, a quality control survey was initiated. Aim: To ensure all CML patients were reported correctly and to identify the cause of possible errors. Materials (or patients) and Methods: Before the 1 st of July 2013 the previous 20 patients with CML treated with allogeneic stem cell transplantation (SCT) were audited for data accuracy (Nov 5 th 2007-July 1 st 2013). The following data were checked for accuracy: diagnosis, date of diagnoses, molecular markers, cytogenetic, pre transplant treatment, and use of thyrosine kinase inhibitors (TKI). The data accuracy was checked in the EBMT, the CIBMTR and the local DB. Data entering have been performed by the EBMT, the CIBMTR and online by the data managers at our institution. Results: For the 20 CML patients, the diagnoses, the date of diagnosis and cytogenetics were reported correctly in all DBs. In relation to all other data, no error was identifi ed in the CIBMTR DB. However, two of 20 patients had a coding error in relation to molecular markers in the EBMT DB, but not in the local DB. In relation to treatment, two patients had a coding error in the EBMT DB and one patient in the local DB. In relation to the fi rst course of TKI treatment three patients had a coding error in the EBMT DB and one in the local DB. In relation to the second course of TKI eight patients had a coding error in the local DB and two in the EBMT DB. Discussion: Conclusion: All data were entered correctly in the CIB-MTR DB, however errors were identifi ed in the EBMT and the local DB. Accordingly, the cause of errors is not related to lack of knowledge of CML biology. The identifi ed errors were not systematically since they did not related to all patients. Therefore it can be assumed that the errors were random data entering errors. When analyzing the data entering process in the three diff erent data bases, the CIBMTR form and DB are identical. However, the MED A form is not identically to the EBMT DB and neither of the forms is identical to the local DB. Therefore interpretation of data during the data entering process may be a source for coding errors. In the future regular audit of data are recommended. Disclosure of Interest: None Declared. Introduction: When analysing GvHD-data we notice that especially for chronic GvHD (cGvHD) a high percentage of data is missing. This is the case in reports from the Austrian Stem Cell Transplant Registry (ASCTR), but also in the EBMT database. Looking at GvHD defi nitions as stated in the MED-AB manual and at data reported by the MED-AB-forms we aimed at assessing the quality of GvHD data as a prerequisite for suggestions to improve data reporting in this important area of hematopoietic cell transplantation (HCT). Materials (or patients) and Methods: In the ASCTR 1616 patients after allogeneic HCT performed between 2000 and 2012 and with a follow-up of at least 3 months are included and in 12% data on acute GvHD (aGvHD) are missing. Furthermore, documentation of aGvHD by severity (grades I to IV) and organ manifestations (skin, liver and gut) has been established excellently by all HCT centers since in only 1% of patients 'grade unknown' has been reported. Regarding cGvHD 23% are coded with having cGvHD, 31% with no cGvHD, 1% unknown and in 45% fi elds are empty. Information on the extent of cGvHD (limited or extensive) is missing in 88%, whereas only 12% miss relapse status, 5% miss main cause of death and reporting on survival status is 100%. Results: The criteria for acute and cGvHD have been amended in the MED-AB manual over the last years. Up to 2011 any GvHD that occurred until day 100 was defi ned as acute and signs of GvHD after day 100 as chronic. Only recently the NIH defi nitions for diff erentiating between "classic acute", "persistent", "recurrent" or "late acute" and "classic cGvHD" as well as "overlap syndrome" have been partly adopted in the EBMT MED-AB manual. cGvHD is still defi ned according to the Seattle classifi cation as "limited" or "extensive" in the EBMT manual and not as "mild", "moderate" or "severe", as in the NIH model. It is possible to register in the follow-up part whether it is late-onset aGvHD, and to diff erentiate in regard to acute and chronic GvHD between: fi rst incidence, recurrence, continuous or resolved cGvHD. However, neither the variables "late onset of aGvHD" nor "persistent", "recurrent" aGvHD nor the "overlap syndrome" are part of the MED-A-form and therefore, hardly any cases have been reported from AT centres. In addition to that, the manual refers to GvHD prevention treatments, but does not explain pre-emptive, fi rst-line, secondline treatment of GvHD and documentation of GvHD treatment is neither implemented in the MED-A nor the MED-B forms. The only exception is the MED-B allograft section for aGvHD reporting at day 100. Discussion: The NIH coding system shows that the reporting of GvHD-data will be even more complex than before. We therefore, suggest to defi ne very few and basic items that are required on day 100 and at follow-up time points but leaving in depth documentation of GvHD for prospective studies and special national and international projects. Of note, training of NIH-defi ned assessment of GvHD and its documentation has already been started by the GvHD Subcommittee of the EBMT. Furthermore, activity of cGvHD can change in follow-up reports depending on response to immunosuppressive treatment and therefore, criteria for response evaluation for GvHD need to be defi ned before data collection and implementation in the EBMT registry software. Items for documentation, their defi nitions and coding options then need to be described in detail in the manual to allow improved data entry into the new database. Disclosure of Interest: None Declared. Because of the availability of innovative Hospital Information Systems (HIS) nowadays, it may also be an opportunity for transplant centers to collect data on a more detailed level. In the UMC Utrecht, the pediatric HSCT team also collects, besides the minimum essential data set required by JACIE (time to engraftment, overall and treatment related morbidity and mortality), additional data such as immune recovery (CD3+ cells), viral reactivation (viral PCR), clinical chemistry lab data and chimerism (STR) data. These data are already available in the HIS, for monitor and treatment purposes, and are automatically captured in a web-based information management application which is compatible with the HIS. This system is also connected to the national donor registry. Aim: It may be of interest for more transplant centers to collect additional data in auto-feed database systems, enlarging their transplant datasets into richer databases. This enables comparing outcome data on more detailed level and allows more sophisticated predictor-analyses for various endpoints (e.g. survival). This may further improve the safety and effi cacy of HSCT. Safer HSCT may result in enlarging the indications for HSCT. Richer databases can also serve as a tool to enable research collaborations between HSCT centers. Materials (or patients) and Methods: Transplant centers, which are interested in collecting and sharing (detailed) transplant data with other dedicated HSCT teams, should have a 'rich' database, preferably auto-fed from the available HIS.The dedicated teams needs to develop guidelines for an objective and reliable data handling, and needs to harmonize the following parameters: -Monitoring of various markers/variables (time and frequency of measuring, e.g. CD3+ cell numbers, viral loads, chimerism).
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-Uniform scoring system and interpretation of test results (e.g. defi nitions of viral reactivation).
-Uniform data analysis (use of statistical models).
-Monitoring of dataset for transparency and reliability of outcome data. Because of a larger spectrum of patients eligible for HSCT, consensus should be achieved to describe the case mix in terms of risk assessment. Results: More detailed transplant data can be collected and shared between HSCT centers by automatic data capture (autofeed database systems) of existing clinical and lab data in the HIS, into a 'HSCT database' . Discussion: With richer databases, comparison of larger similar patient groups between centers can be improved, leading to more meaningful conclusions. Furthermore, adjustments in treatment regimens can be evaluated in more detail, aiming at safer treatment and better quality-of-life of the patients. Disclosure of Interest: None Declared.
